Navigation Links
Experimental Drug Fights Prostate Cancer
Date:11/7/2007

In mice, it attacked disease on multiple fronts, researchers say

WEDNESDAY, Nov. 7 (HealthDay News) -- In mice, an investigational agent called VN/14-1 proved effective in treating human prostate cancer, say researchers at the University of Maryland in Baltimore.

The five-week study found that daily injections of VN/14-1 in mice implanted with human prostate cancer cells resulted in up to a 50 percent reduction in tumor volume.

VN/14-1 blocks the breakdown of vitamin A-derived retinoic acid, the researchers explained. The drug appears to tackle cancer in multiple ways.

"This potent agent causes cancer cells to differentiate, forcing them to turn back to a non-cancerous state -- which is what we expected it would do -- but it also stops cancer growth by arresting the cell cycle and pushes cells to die by inducing programmed cell death," senior investigator Vincent C.O. Njar, associate professor in the department of pharmacology and experimental therapeutics in the School of Medicine, said in a prepared statement.

"These functions were unexpected and wonderfully surprising. I am not aware that any drug currently used to treat prostate cancer targets so many pathways," said Njar, whose lab developed VN/14-1.

The findings were to be presented Tuesday at an American Association for Cancer Research meeting.

Vitamin A is converted by the body into retinoic acid, which maintains the normal growth of cells. Prostate cancer cells contain five to eight times less retinoic acid than normal prostate cells. VN/14-1 is designed to block the breakdown of retinoic acid in cancer cells.

More information

The American Academy of Family Physicians outlines prostate cancer treatment options.



-- Robert Preidt



SOURCE: American Association for Cancer Research, news release, Nov. 6, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Guacamole: Fights Hunger, Cholesterol and Cancer
8. Two-Drug Combo Fights Brain Tumors
9. Connecticut Girl Fights Rare Neurological Disease
10. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... ... An intensive search of the medical literature has revealed no research yet on ... He says investigating this possibility, is important because Miami-Dade in 2016 led the U.S. ... , His findings appear on Analizir.com. . Dr. Norins, who trained ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Last year, 43 ... a US Department of Agriculture report. While excess dairy can be caused by ... role. Lactose sensitivity is the inability to properly digest lactose, a sugar found in ...
(Date:3/22/2017)... ... 22, 2017 , ... The Vanderbeck Agency, a Long Island firm providing insurance, ... embarking on a combined charity effort with the Great Neck Breast Cancer Coalition to ... the Great Neck Breast Cancer Coalition has worked to support breast cancer patients in ...
(Date:3/22/2017)... ... 2017 , ... The Zabbia Insurance Agency, a Long Island ... owners in the greater Nassau County area, is embarking on a cancer awareness ... minutes, someone in America is diagnosed with blood cancer. Every 9 minutes, someone ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Senior Citizens League (TSCL) is ... default on the federal debt — including the debt held by the Social Security ... said TSCL in a letter to House and Senate budget leaders. “In prior ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017  Ablation is ... for a wide range of purposes, from cancerous ... abnormally conducting cardiac tissue in atrial fibrillation and ... is pushing the researchers to innovate and improvise ... The ablation device global market is expected ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
(Date:3/22/2017)... March 22, 2017 A new independent ... is the proven ultraviolet-C (UV-C) disinfection solution of ... (HAIs). Published in the March ... Control , the peer-reviewed study of UV-C disinfection ... Vancouver General Hospital and Rochester General Hospital. According ...
Breaking Medicine Technology: